⌕
Intellia Therapeutics · NTLA · Nasdaq
Tenet 41 · Weak
Compare
$9.78−0.81%At closeTenet 41 · Weak
$9.78−0.08 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Intellia Therapeutics (NTLA) Stock

Intellia Therapeutics (NTLA) closed at $9.78 on Nov 17, 2026; its Tenet Score is 41 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

25 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$9.78
Nov 17, 2026
Market cap
$1.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
7.95 – 18.48
low → high · as of close, Nov 16, 2026
Tenet Score
41/100
Weak · 340 Healthcare peers

Industry: Drugs

Intellia Therapeutics Inc scores 41/100. Weak. Strongest on value and financial health, quality is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
41/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
76
Quality
9
Health
70
Growth
9

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityFHealthBGrowthFMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.3×
Sep 30, 2026 balance sheet
P/S
26.2×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−63%
TTM through Sep 30, 2026
Operating margin
−651.7%
fiscal 2025, before interest and tax
Net margin
−805.7%
TTM through Sep 30, 2026
Current ratio
6.31
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the tre…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 77 US ETFs · top wrappers by weightSee all ETFs holding NTLA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

Compare Intellia Therapeutics with

What sector and industry is Intellia Therapeutics in?

Intellia Therapeutics is in the Healthcare sector and the Drugs industry.

What is Intellia Therapeutics' Tenet Score?

Intellia Therapeutics' Tenet Score is 41 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.